GFAP holds potential as a biomarker of disease progression.
Serum neurofilament light (NfL), derived from neurons, is associated with relapse-associated confirmed disability progression in multiple sclerosis (MS). A marker for progression independent of relapses (PIRA) is needed. One candidate is serum glial fibrillary acidic protein (GFAP), a filament of astrocytes. These investigators examined serum GFAP and NfL levels in a longitudinal cohort of 103 patients with progressive MS (PMS) or relapsing MS (RMS). The PMS patients were further divided into progressing or stable and RMS patients into active or remission disease intervals. They also studied a cross-sectional cohort of 252 patients treated with B-cell depleting drugs.
GFAP levels were highest in worsening PMS, followed by active RMS, stable …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)